Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …

Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-
small cell lung cancer (NSCLC), but its efficacy and impact on the immune …

Background Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally
advanced stage disease. We aimed to assess the antitumour activity and safety of …

Background Previous phase 2 trials of neoadjuvant anti-PD-1 or anti-PD-L1 monotherapy in
patients with early-stage non-small-cell lung cancer have reported major pathological …

The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary
discussions of surgical resectability and medical operability determine the modality of …

PURPOSE For patients with resectable stage IIIA (N2) non–small-cell lung cancer,
neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1 …

Therapeutic strategies harnessing the immune system to eliminate tumour cells have been
successfully used for several cancer types, including in patients with advanced-stage non …

Cisplatin-based adjuvant chemotherapy remains the standard of care for patients with
resected stage II or III non–small-cell lung cancer. However, biomarker-informed clinical …